Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives

Patent metadata

Field	Value
Publication number	US-12178790-B2
Application number	US-202117394572-A
Country	US
Kind code	B2
Filing date	Aug 5, 2021
Priority date	Aug 5, 2021
Publication date	Dec 31, 2024
Grant date	Dec 31, 2024

Abstract

Aspidin BB derivatives, compositions containing them, and methods of making and using them.

First claim

The invention claimed is:

1. A method of treating a microbial infection, the method comprising administering a composition comprising an isolated aspidin of formula (II)

to a patient in need thereof.

2. The method according to claim 1 , wherein said microbial infection is a bacterial infection.

3. The method according to claim 2 , wherein said bacterial infection is an infection by a gram-positive bacterial strain.

4. The method according to claim 3 , wherein said gram-positive bacterial strain is chosen from Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus argenteus, Staphylococcus haemolyticus, Staphylococcus warnieri, Staphylococcus lugdunensis, Corynebacterium diphteriae, Corynebacterium minutissimum, Corynebacterium acnes ( Propionibacterium acnes ) , Corynebacterium sp., Bacillus cereus, Bacillus subtilis, Bacillus anthracis, Bacillus sp., Enterococcus faecium, Enterococcus faecalis, Enterococcus sp., Nocardia abscessus, Nocardia farcinica, Nocardia asteroides, Nocardia cyriacigeorgica, Nocardia brasiliensis, Nocardia brevicatena, Nocardia paucivorans, Nocardia nova, Nocardia transvalensis, Nocardia sp., Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus mutans , and Streptococcus sp.

5. The method according to claim 4 , wherein said Staphylococcus aureus strain is a methicillin-resistant Staphylococcus aureus or a vancomycin-resistant Staphyloccocus aureus.

6. The method according to claim 2 , wherein the bacterial strain is a gram -negative bacterial strain.

7. The method according to claim 6 , wherein said gram-negative bacterial strain is chosen from Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.

8. The method according to claim 6 , further comprising administering at least one outer membrane permeabilizer.

9. The method of claim 8 , wherein the at least one outer membrane permeabilizer is a polymyxin.

10. The method of claim 9 , wherein the polymyxin is colistin.

11. The method according to claim 1 , wherein the microbial infection is a fungal infection selected from the group consisting of Candida albicans, Candida parapsilosis, Candida glabrata, Candida tropicalis, Cryptococcus neoformans, Cryptococcus gatti, Pneumocystis jirovecii, Aspergillus fumigatus, Aspergillus flavus, Aspergillus nidulans, Aspergillus versicolor, Aspergillus niger, Aspergillus terreus, Histoplasma capsulatum, H. capsulatum duboisii , and Torulopsis glabrata.

Assignees

• Centre Nat Rech Scient
• Sorres Jonathan

Inventors

• Sorres Jonathan
• Eparvier Véronique

Classifications

• A61Q19/007

  Preparations for dry skin · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61Q19/02

  for chemically bleaching or whitening the skin · CPC title

• A61Q19/08

  Anti-ageing preparations · CPC title

• A61P31/10

  Antimycotics · CPC title